MedTrace Logo

Carry Life@ UF System Clinical Study

NCT05874804 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-12-22

No results posted yet for this study

Summary

The Carry Life UF system performs peritoneal ultrafiltration by adding glucose to the low glucose strength (1.36%) peritoneal dialysis fluid which has been instilled into the peritoneal cavity prior to the connection of the device. By maintaining a stable glucose concentration in the intraperitoneal fluid during the 5-hour treatment, the ultrafiltration can be increased compared to a standard CAPD dwell.

Conditions

Interventions

DEVICE

Carry Life UF

A 5-hour treatment with the Carry Life UF used with a 1.36% glucose PD fill.

DRUG

2.27% glucose peritoneal dialysis dwell

A 5-hour CAPD dwell with a 2.27% glucose PD fluid.

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Triomed AB

    lead INDUSTRY

Principal Investigators

  • Olof Heimbürger, MD, PhD · Karolinska Institutet

  • Stanley Fan, MD, PhD · Barts & The London NHS Trust

  • Giuseppe Castellano, MD, PhD · Policlinic of Milan, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-19
Primary Completion
2025-10-24
Completion
2025-11-04

Countries

  • Italy
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05874804 on ClinicalTrials.gov